The estimated Net Worth of Thomas John Dietz is at least $550 millier dollars as of 23 January 2023. Thomas Dietz owns over 50,000 units of Eiger BioPharmaceuticals Inc stock worth over $86,250 and over the last 10 years he sold EIGR stock worth over $124,350. In addition, he makes $339,162 as Independent Chairman of the Board at Eiger BioPharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Dietz EIGR stock SEC Form 4 insiders trading
Thomas has made over 12 trades of the Eiger BioPharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of EIGR stock worth $71,500 on 23 January 2023.
The largest trade he's ever made was buying 50,000 units of Eiger BioPharmaceuticals Inc stock on 23 January 2023 worth over $71,500. On average, Thomas trades about 2,661 units every 42 days since 2015. As of 23 January 2023 he still owns at least 50,000 units of Eiger BioPharmaceuticals Inc stock.
You can see the complete history of Thomas Dietz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Dietz biography
Dr. Thomas J. Dietz Ph.D. serves as Independent Chairman of the Board of the Company. He has been a member of Private Eiger’s board of directors since his appointment in October 2015 and assumed the same position at the Company in March 2016. Dr. Dietz has served as Chairman and CEO of Waypoint Holdings, LLC, a financial services firm, since December 2010. Dr. Dietz was previously co-CEO and then CEO and a director of Pacific Growth Equities, LLC, an investment bank and institutional brokerage firm, from 2004 to January 2009, when the firm was acquired by Wedbush Securities, a financial services firm. Dr. Dietz subsequently served as head of the investment banking division at Wedbush until November 2010. Dr. Dietz joined Pacific Growth in 1993 and served in various roles, including senior roles in equities research and investment banking, prior to taking the CEO role there. Previously, Dr. Dietz was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University in St. Louis. Dietz’s qualifications to sit on the board of directors include his medical and research background and extensive finance and executive experience in the financial services industry.
What is the salary of Thomas Dietz?
As the Independent Chairman of the Board of Eiger BioPharmaceuticals Inc, the total compensation of Thomas Dietz at Eiger BioPharmaceuticals Inc is $339,162. There are 10 executives at Eiger BioPharmaceuticals Inc getting paid more, with David Cory having the highest compensation of $2,871,850.
How old is Thomas Dietz?
Thomas Dietz is 56, he's been the Independent Chairman of the Board of Eiger BioPharmaceuticals Inc since 2019. There are 9 older and 7 younger executives at Eiger BioPharmaceuticals Inc. The oldest executive at Eiger BioPharmaceuticals Inc is Dr. Colin Hislop, 63, who is the Sr. VP of Clinical & Devel. Operations.
What's Thomas Dietz's mailing address?
Thomas's mailing address filed with the SEC is C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE, MA, 02141.
Insiders trading at Eiger BioPharmaceuticals Inc
Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman et Partners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.
What does Eiger BioPharmaceuticals Inc do?
eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.
What does Eiger BioPharmaceuticals Inc's logo look like?
Complete history of Thomas Dietz stock trades at Eiger BioPharmaceuticals Inc, Leap Therapeutics Inc et Paratek Pharmaceuticals
Eiger BioPharmaceuticals Inc executives and stock owners
Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
David Cory,
President, Chief Executive Officer, Director -
David Apelian,
Director -
Stephana Patton,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Sriram Ryali,
Chief Financial Officer -
David A. Cory M.B.A., R.Ph., R.Ph, MBA,
Bus. Founder, Pres, CEO & Director -
James Shaffer,
Chief Business Officer -
David A. Cory R.Ph, MBA,
Bus. Founder, Pres, CEO & Director -
Eldon C. Mayer III, M.B.A.,
Exec. VP & Chief Commercial Officer -
Sriram Ryali M.B.A.,
Chief Financial Officer -
Christine Murray,
Independent Director -
Thomas Dietz,
Independent Chairman of the Board -
Amit Sachdev,
Independent Director -
Evan Loh,
Independent Director -
Eldon Mayer,
Executive Vice President, Chief Commercial Officer -
Jeffrey Glenn,
Independent Director -
Dr. Evan Loh,
CEO of Paratek Pharmaceuticals & Director -
Dr. Jeffrey S. Glenn,
Founder, Scientific Advisor & Independent Director -
Dr. Stephana E. Patton J.D., Ph.D.,
Consultant -
Erik Atkisson,
Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Dr. Colin Hislop,
Sr. VP of Clinical & Devel. Operations -
Rich Franco M.B.A.,
Sr. VP & Progeria Program Lead -
Dr. Ingrid C. Choong,
Sr. VP of Clinical Devel. -
Charles Bramlage,
Director -
Edgar Engleman,
Director -
Joanne Quan,
Chief Medical Officer -
Eduardo Bruno Martins,
SVP, Liver and Infectious Dise -
Ventures Vi, Llc Vivo Ventu...,
-
James H Welch,
Chief Financial Officer -
Nina S Kjellson,
Director -
Kim Sablich,
-
Partners X Lp Inter West Ma...,
-
Ingrid Choong,
Chief Business Officer -
Erik Atkisson,
GC & Chief Compliance Officer -
Lisa Kelly Croswell,
-
James Vollins,
General Counsel -
Leen Kawas,
-
Richard A Kayne,